روند روزانه سهام شرکت
Abeona Therapeutics Inc.
این نمودار بصورت روزانه به روز رسانی می گردد
|نام شرکت||نماد||سرمایه (میلیون دلار)||کشور||عرضه اولیه||زیر مجموعه|
|Abeona Therapeutics Inc.||ABEO||۳۵۰٫۲۲||United States||N/A||Major Pharmaceuticals|
About Abeona: Abeona Therapeutics, Inc. develops and delivers gene therapy and plasma-based products for severe and life-threatening rare diseases. Abeona’s lead programs are AB0-101 (AAV9 NAGLU) and ABO-102 (scAAV9 SGSH), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA) in collaboration with patient advocate groups, researchers and clinicians, anticipated to commence clinical trials in 2015. We are also developing ABO-201 (scAAV9 CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV LK19 FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. In addition, we are also developing rare plasma protein therapies including SDF Alpha(TM) (alpha-1 protease inhibitor) for inherited COPD using our proprietary SDF(TM) (Salt Diafiltration) ethanol-free process. For more information, visit www.abeonatherapeutics.com.